Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 43 Publications

Nature, 2016, 538(7626):477-482

PubMed: 27760111

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795

Blood, 2013, 121(10):1850-7

PubMed: 23303820

Blood, 2013, 122(9):1587-98

PubMed: 23881917

Blood, 2011, 117(26):7145-54

PubMed: 21562047

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444

Leukemia, 2016, 30(2):351-60

PubMed: 26488112

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615
Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651

Chem Sci, 2014, 5, 2794–2803

PubMed:

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075
Cell Death Dis, 2013, 4:e883

PubMed: 24157877

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed:

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522
Transfusion, 2012, 52(10):2094-103

PubMed: 22320126

Open Biol, 2015, 5(3)

PubMed: 25761368

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320

PLoS One, 2011, 6(9):e24590

PubMed: 21931768

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278

Microvasc Res, 2015, 101:72-81

PubMed: 26122935

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

13 Customer Reviews

KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.
ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

(A) In vitro generated Mcl-1-deleted Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM. p185+ Arf-/- cells serve as a control. (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or (E) IM or (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

Navitoclax (ABT-263) purchased from Selleck.
Human Ph+ cell lines: (A) OP-1 Ph+ B-ALL (B) TOM1 Ph+ B-ALL and (C) BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL. For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmruTWM2OD1yLkCwOlY6KM7:TR?=	NXXTUnhrW0GQR1XS
MV-4-11	NIi0UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMEG1PFYh\|ryP	NXHNNVE2W0GQR1XS
NKM-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEG2PVkh\|ryP	M2q3eXNCVkeHUh?=
ML-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XWZmlEPTB;MD6wNVk5OyEQvF2=	NULtXI56W0GQR1XS
BV-173	M{L3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEKzNVQh\|ryP	M3TvWnNCVkeHUh?=
RS4-11	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEK1PFch\|ryP	M1XRXHNCVkeHUh?=
HL-60	NH2x[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMEK5NFgh\|ryP	M2HxTnNCVkeHUh?=
KY821	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmX5TWM2OD1yLkCyPVc2KM7:TR?=	M33ucXNCVkeHUh?=
ECC10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HJOmlEPTB;MD6wN\|c6OiEQvF2=	Mlq0V2FPT0WU
NCI-H720	NYXTdWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMESwNVEh\|ryP	MWPTRW5ITVJ?
QIMR-WIL	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFm4SldKSzVyPUCuNFQzQDdizszN	M{DsdnNCVkeHUh?=
KG-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnUV4ZKSzVyPUCuNFQ1QDZizszN	MV3TRW5ITVJ?
TGW	NGXh[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMES2N\|Mh\|ryP	Mn[1V2FPT0WU
ATN-1	M4DrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHqdYI1UUN3ME2wMlA1PzN\|IN88US=>	NFH2VlVUSU6JRWK=
RH-18	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7ETWM2OD1yLkC2NFQ5KM7:TR?=	MUfTRW5ITVJ?
EW-18	M{OzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXsSJU{UUN3ME2wMlA3QDRzIN88US=>	MV3TRW5ITVJ?
NB17	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEexNlQh\|ryP	NGDS[pdUSU6JRWK=
SK-NEP-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX0TWM2OD1yLkC3NlE{KM7:TR?=	MVPTRW5ITVJ?
P12-ICHIKAWA	NILPdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHSZWRKSzVyPUCuNFc4PzhizszN	NWnWSpdJW0GQR1XS
KARPAS-45	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DPbWlEPTB;MD6wO\|gyPSEQvF2=	MXXTRW5ITVJ?
EW-3	M3PpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2e5b2lEPTB;MD6wPFA2OyEQvF2=	MVPTRW5ITVJ?
NB13	M17pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7wUmdKSzVyPUCuNFgzODNizszN	MoCyV2FPT0WU
NCI-H209	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEi3NFQh\|ryP	MXXTRW5ITVJ?
NCI-H1092	NVTqXmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3UfIJKSzVyPUCuNVAzPzVizszN	NFfNe5pUSU6JRWK=
NH-12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMUC3OFQh\|ryP	NXGzNYNpW0GQR1XS
697	M2\Y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfsSJdKSzVyPUCuNVA5OzlizszN	NYfF[Zd5W0GQR1XS
KE-37	M1T1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrPTWM2OD1yLkGxN\|ch\|ryP	NH;CbJRUSU6JRWK=
MOLT-4	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\Wb2lEPTB;MD6xOVE3QSEQvF2=	MWLTRW5ITVJ?
CHP-134	M1GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfZNmRKSzVyPUCuNVY{ODZizszN	NVTme5lqW0GQR1XS
D-283MED	NXewTJd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlv5TWM2OD1yLkG3Olg3KM7:TR?=	MWjTRW5ITVJ?
LU-135	NYqwXoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj0NoVKSzVyPUCuNVg2PTJizszN	NHz1S2dUSU6JRWK=
LU-134-A	M4rKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;jfnpKSzVyPUCuNVg3PzFizszN	MoTyV2FPT0WU
EM-2	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMUm5NVgh\|ryP	MUTTRW5ITVJ?
LU-139	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfKW3RTUUN3ME2wMlIxPDl6IN88US=>	NH72PGpUSU6JRWK=
ALL-PO	NGXpTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7rU5JsUUN3ME2wMlIyQTh6IN88US=>	MkHxV2FPT0WU
NB12	NEPMXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LqfWlEPTB;MD6yN\|EyPSEQvF2=	M13ZbnNCVkeHUh?=
KP-N-YN	M2TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvV[IE6UUN3ME2wMlI{PTd\|IN88US=>	M4PvSHNCVkeHUh?=
BEN	NHTjUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTJfYR7UUN3ME2wMlI{QTZ6IN88US=>	MnvwV2FPT0WU
HCC1569	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMkWxNFYh\|ryP	NV3VTGozW0GQR1XS
HuO9	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1OyT2lEPTB;MD6yOlcyPSEQvF2=	M1XSWXNCVkeHUh?=
WM-115	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvxUGxKSzVyPUCuNlc4OzhizszN	M2n0[HNCVkeHUh?=
CCRF-CEM	NFHET3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnCOHhKSzVyPUCuN\|M2OjlizszN	MXrTRW5ITVJ?
IST-SL1	NGDCdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXxSnpKSzVyPUCuN\|U{PDNizszN	NFWye4hUSU6JRWK=
BE-13	NV;sUpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwM{[0OVkh\|ryP	NVHOXpVqW0GQR1XS
COR-L88	NXXvcWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPjcoFYUUN3ME2wMlM3PTRizszN	MY\TRW5ITVJ?
DOHH-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNEGwNlMh\|ryP	NUGyZ2NRW0GQR1XS
A704	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXwTWM2OD1yLkSyOlch\|ryP	Mny4V2FPT0WU
KNS-81-FD	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNESwNVch\|ryP	NIrBeIhUSU6JRWK=
RPMI-8226	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPuTWM2OD1yLkS1OlUzKM7:TR?=	NHLyOHVUSU6JRWK=
TGBC24TKB	NWfMSXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFy2e3RKSzVyPUCuOFU4PzhizszN	M{HLTnNCVkeHUh?=
NCI-H1304	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPLSlVKSzVyPUCuOFYyPTdizszN	Mo\EV2FPT0WU
MOLT-13	NYLhdZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG1e2JKSzVyPUCuOFY3OTNizszN	NV:3bHVqW0GQR1XS
EW-22	NYX4XJBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNE[2O\|Eh\|ryP	NVnKUWtRW0GQR1XS
MS-1	NYDabGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;QTWM2OD1yLkS2PVM{KM7:TR?=	MmXsV2FPT0WU
RMG-I	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW3TWM2OD1yLkS5OFY1KM7:TR?=	NEf5S5ZUSU6JRWK=
NTERA-S-cl-D1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HBXmlEPTB;MD61NFAyQSEQvF2=	MVPTRW5ITVJ?
NCI-H1048	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki2TWM2OD1yLkWwPVU{KM7:TR?=	MV7TRW5ITVJ?
SW1417	M4LoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzOTWM2OD1yLkW1OFM5KM7:TR?=	MYLTRW5ITVJ?
DB	NGjWW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHCenp[UUN3ME2wMlU4ODhizszN	NH7RZYpUSU6JRWK=
MEG-01	NHrobG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCyTWM2OD1yLkW4N\|Ih\|ryP	NHTJ[G5USU6JRWK=
EW-13	M1PnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7zTWM2OD1yLkW4N\|QyKM7:TR?=	Ml3IV2FPT0WU
LAMA-84	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX23W\|Y3UUN3ME2wMlU6OjB5IN88US=>	MWPTRW5ITVJ?
J-RT3-T3-5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwNkC4NFgh\|ryP	MWnTRW5ITVJ?
MOLT-16	NYS3XYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIW2W2NKSzVyPUCuOlUzPjRizszN	MUDTRW5ITVJ?
DU-4475	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX1fotwUUN3ME2wMlY2PDJ5IN88US=>	MnfqV2FPT0WU
HAL-01	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIflS3JKSzVyPUCuO\|I2PDlizszN	NVXUfIZwW0GQR1XS
RD	NYn2VFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwN{W4PVkh\|ryP	NYXYNJdEW0GQR1XS
OAW-28	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1focmlEPTB;MD63PFM4KM7:TR?=	NWXMT3N6W0GQR1XS
HCC38	M{HsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfJTWM2OD1yLkiwNVkh\|ryP	NWeyNmFpW0GQR1XS
NMC-G1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwOEGxNlEh\|ryP	M{XDcHNCVkeHUh?=
EW-16	NGjXe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwOEGzNlgh\|ryP	NIqyRVlUSU6JRWK=
DU-145	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwOEm5NlMh\|ryP	MULTRW5ITVJ?
HPAF-II	M4LVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe3TFlmUUN3ME2wMlkzPjJ6IN88US=>	NXuyeHRuW0GQR1XS
A427	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DZc2lEPTB;MD65N\|AzOiEQvF2=	MmDSV2FPT0WU
PA-1	NGHjTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPuZYhKSzVyPUCuPVU3PDJizszN	NUXNNWdDW0GQR1XS
OAW-42	NV7SS3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjmZmt2UUN3ME2wMlk3OTR4IN88US=>	M37OS3NCVkeHUh?=
L-428	NGPQTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljsTWM2OD1zLkCxNlUh\|ryP	NWf0XHRqW0GQR1XS
COLO-824	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m5SmlEPTB;MT6wNVcxQCEQvF2=	Mon5V2FPT0WU
P30-OHK	NHHP[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rX[WlEPTB;MT6wOFY5QCEQvF2=	MojiV2FPT0WU
NCI-H2170	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[xTWM2OD1zLkC2NlMh\|ryP	M3vWdXNCVkeHUh?=
HCC2998	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HtPGlEPTB;MT6wO\|E{PSEQvF2=	MoG3V2FPT0WU
NB14	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTFwMUO3OFgh\|ryP	M3nmS3NCVkeHUh?=
TGBC1TKB	NYjZcWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTxTWM2OD1zLkG0NVUzKM7:TR?=	NH\nU3VUSU6JRWK=
KP-N-YS	NWrEcmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XxXWlEPTB;MT6xOlI{PiEQvF2=	NUfibpEyW0GQR1XS
CAL-120	M{HyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTFwMU[0Nlkh\|ryP	MofSV2FPT0WU
SBC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTFwMUmwOVMh\|ryP	MmLyV2FPT0WU
C32	MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwMUmwPFgh\|ryP	M{nDTXNCVkeHUh?=
HCC2157	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nSOGlEPTB;MT6xPVQ6PCEQvF2=	NVrSWJRXW0GQR1XS
COLO-792	NH7v[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfkTWM2OD1zLkKwNFcyKM7:TR?=	NHnyXJRUSU6JRWK=
ES7	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwMke5OVEh\|ryP	M4HQTXNCVkeHUh?=
HEL	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHjTWM2OD1zLkOxNFI6KM7:TR?=	NYXDbIp7W0GQR1XS
ES4	NUnkcHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\oTWM2OD1zLkO0PVk5KM7:TR?=	MlLDV2FPT0WU
NCI-SNU-1	M33SbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwM{[1OVUh\|ryP	NITsfWtUSU6JRWK=
MDA-MB-415	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PRcGlEPTB;MT6zPFg2KM7:TR?=	M{HZVnNCVkeHUh?=
NCI-H2342	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTFwNECyOlkh\|ryP	NWLRdI4{W0GQR1XS
NB69	NHXERmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH25UlNKSzVyPUGuOFYzPzFizszN	Mo\DV2FPT0WU
D-247MG	NWDs[3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;DT2lEPTB;MT61NVEzOiEQvF2=	Mlv2V2FPT0WU
SCC-4	NIrpNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwNUm4PFch\|ryP	NHrjS\|hUSU6JRWK=
HuH-7	M2D3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PxW2lEPTB;MT62O\|I6OyEQvF2=	MoLrV2FPT0WU
A388	M3HjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD2UJBSUUN3ME2xMlY5PzJ2IN88US=>	NI\ZPINUSU6JRWK=
Calu-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXFZodKSzVyPUGuO\|A3QTdizszN	NUS4PZFiW0GQR1XS
NCI-H1648	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTFwN{G0NVgh\|ryP	MYnTRW5ITVJ?
NCI-H2052	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTNPW5XUUN3ME2xMlczOjBzIN88US=>	NHHTbmlUSU6JRWK=
Ramos-2G6-4C10	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTFwN{O2OVYh\|ryP	NG\RRoJUSU6JRWK=
DEL	NGfwfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXXeFZKSzVyPUGuO\|Q3QTJizszN	M1WzUnNCVkeHUh?=
SNU-423	NF7jfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn2TWM2OD1zLke4NVU4KM7:TR?=	M4\xWnNCVkeHUh?=
COR-L23	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDyTWM2OD1zLke5PFc1KM7:TR?=	MlPGV2FPT0WU
OMC-1	NVTGbW17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLPTWM2OD1zLki2NFE3KM7:TR?=	M2[2e3NCVkeHUh?=
EW-11	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTFwOUW2OVch\|ryP	NYC5XFV5W0GQR1XS
HSC-3	NY\zbZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\LbmtKSzVyPUGuPVY{PjVizszN	Mnv1V2FPT0WU
MLMA	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwOU[2O\|ch\|ryP	MXHTRW5ITVJ?
RCM-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fIUmlEPTB;Mj6wNFM6QSEQvF2=	MVzTRW5ITVJ?
MFE-280	NIfYZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjlTWM2OD1{LkCyPFQ5KM7:TR?=	NW\ofWJNW0GQR1XS
ES8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjkVHhKSzVyPUKuNlU1PzFizszN	NWm1e2d6W0GQR1XS
TE-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHkTWM2OD1{LkK5OFc{KM7:TR?=	MXTTRW5ITVJ?
HuO-3N1	NUS4XFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzqTJhKSzVyPUKuOFg4QCEQvF2=	NFrCV4tUSU6JRWK=
MHH-NB-11	M171Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJwNUGxOVgh\|ryP	NVvXNnE{W0GQR1XS
TGBC11TKB	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7MbGRKSzVyPUKuOVc3QDFizszN	M2DEeXNCVkeHUh?=
HOP-92	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PTdmlEPTB;Mj61PFc1OyEQvF2=	MoToV2FPT0WU
IGR-1	NGXXUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\SRYZKSzVyPUKuOlIxOzVizszN	NWHzfYZxW0GQR1XS
GOTO	NHi4OZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TNR2lEPTB;Mj62OVM4PyEQvF2=	MWnTRW5ITVJ?
NCI-H1650	M4XYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLvVJBmUUN3ME2yMlczOjF3IN88US=>	NWPDPHpFW0GQR1XS
NCI-H1581	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWGweWhEUUN3ME2yMlc6PjhzIN88US=>	NEPrboJUSU6JRWK=
NCI-H2405	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLPTWM2OD1{LkiyO\|gzKM7:TR?=	M4D5VHNCVkeHUh?=
U-118-MG	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Pp[WlEPTB;Mj65OlQ6OSEQvF2=	NVvWOHFJW0GQR1XS
DoTc2-4510	NWnkcWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTNwMEG0NVch\|ryP	NGLGd2RUSU6JRWK=
NCI-H596	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ywWmlEPTB;Mz6wOFk6PyEQvF2=	M3XX[XNCVkeHUh?=
MPP-89	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV33XWZDUUN3ME2zMlA2PjZ4IN88US=>	MkPVV2FPT0WU
GCIY	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX3OlFKSzVyPUOuNlA1QTFizszN	NWnIR282W0GQR1XS
SW626	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTNwMkS1OFMh\|ryP	Mnv1V2FPT0WU
OCI-AML2	NXG5eVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\DZWlEPTB;Mz6zNVI4OiEQvF2=	NIHU[lBUSU6JRWK=
NBsusSR	NFW1dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[z[HgzUUN3ME2zMlM1QTN6IN88US=>	NVjUVJNbW0GQR1XS
AN3-CA	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTNwNESyN\|gh\|ryP	NIHzNJZUSU6JRWK=
EFM-19	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL6TWM2OD1\|LkS4N\|M6KM7:TR?=	NHPhT4VUSU6JRWK=
RVH-421	NIf4[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nsNGlEPTB;Mz61Olg4PyEQvF2=	NFjYfpVUSU6JRWK=
5637	MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVO1OIlCUUN3ME2zMlYyOTB\|IN88US=>	NV3jb417W0GQR1XS
PANC-08-13	NHLSenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnvUIdKSzVyPUOuOlM1PzJizszN	Mn\wV2FPT0WU
H9	MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDMW2lKSzVyPUOuOlcyPDRizszN	NHX4VItUSU6JRWK=
KARPAS-299	NV7UfHhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHxTWM2OD1\|Lk[3N\|YyKM7:TR?=	M4nzZnNCVkeHUh?=
TE-5	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rVUWlEPTB;Mz63NFcxQSEQvF2=	M1ziXXNCVkeHUh?=
NOS-1	NIC1PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TITGlEPTB;Mz63PVg{PCEQvF2=	MWPTRW5ITVJ?
HH	M3rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;wR5FKSzVyPUOuPFM5PjhizszN	M4TWWHNCVkeHUh?=
769-P	M4r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjNTWM2OD1\|Lki5OVEh\|ryP	MXzTRW5ITVJ?
CHP-212	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C5N2lEPTB;Mz65NlU1QSEQvF2=	NUXHPJJUW0GQR1XS
NCI-H82	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXIU2lKSzVyPUOuPVU6OzZizszN	MoLMV2FPT0WU
Mo-T	M{jpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjqVpJSUUN3ME20MlA1OzF{IN88US=>	MWHTRW5ITVJ?
BB65-RCC	NEPNUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXTe\|RMUUN3ME20MlA1Ozl7IN88US=>	NVX5foJtW0GQR1XS
SW1990	M2XzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;wRoVKSzVyPUSuNFU6ODhizszN	MXfTRW5ITVJ?
LK-2	NW[2b4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TRNWlEPTB;ND6xNVI6OyEQvF2=	MUHTRW5ITVJ?
ES5	M3fF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrJV4dKSzVyPUSuNVM6QDVizszN	M13YenNCVkeHUh?=
JVM-3	NHzmXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{iwTGlEPTB;ND6xPFIzOiEQvF2=	M2\2c3NCVkeHUh?=
RPMI-7951	NED1cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37PTWlEPTB;ND6yNlQyOyEQvF2=	M3fObHNCVkeHUh?=
Calu-6	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7RUG1KSzVyPUSuNlc5QDFizszN	NUHoToxZW0GQR1XS
LC-2-ad	NXvDT\|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDVT2JKSzVyPUSuNlk2PjhizszN	NH;ZUIJUSU6JRWK=
SW954	NFfXcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrRTWM2OD12LkK5OlYh\|ryP	MlTZV2FPT0WU
H-EMC-SS	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Lq[mlEPTB;ND6zNVg{OSEQvF2=	NWjZcIc1W0GQR1XS
ES3	M4nV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXKTWM2OD12LkO1OFQyKM7:TR?=	MkDLV2FPT0WU
no-11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHqTWM2OD12LkO1OVU1KM7:TR?=	MoLjV2FPT0WU
LAN-6	NEXhUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqwNYNKSzVyPUSuOFUyQDlizszN	NHzyZpZUSU6JRWK=
FTC-133	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\mVGlEPTB;ND61N\|k2KM7:TR?=	M3rYZXNCVkeHUh?=
8505C	M2H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\aTWM2OD12LkW0NlMh\|ryP	NVLPSYo4W0GQR1XS
SW620	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHYfIhKSzVyPUSuOVcxPTdizszN	MYHTRW5ITVJ?
BCPAP	NEHWc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrvbXJKSzVyPUSuOlM1QDFizszN	NWS5TFRiW0GQR1XS
SK-LU-1	NY\NTpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PnemlEPTB;ND62OlA5QSEQvF2=	M3;IWXNCVkeHUh?=
NCI-H1623	NEXzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrrTWM2OD12LkewNlI5KM7:TR?=	NVu5[ZVpW0GQR1XS
C2BBe1	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:wfXhKSzVyPUSuO\|QxODhizszN	M4SwSXNCVkeHUh?=
GP5d	NULs[YJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfyZZlKSzVyPUSuO\|g{QDhizszN	MVPTRW5ITVJ?
NB6	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET3SlFKSzVyPUSuPFYzODRizszN	MV\TRW5ITVJ?
MDA-MB-157	M1LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXCTWM2OD12Lki4O\|Yh\|ryP	NWrzfm9oW0GQR1XS
UMC-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTRwOEi5OlQh\|ryP	MUHTRW5ITVJ?
HCC1419	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPhTWM2OD12LkmwNFY{KM7:TR?=	MYnTRW5ITVJ?
NCI-H2029	NX\HdWxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTRwOUSxPFUh\|ryP	MUDTRW5ITVJ?
LXF-289	NEjhNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPVcZk2UUN3ME21MlA{PzF7IN88US=>	NX;h[od2W0GQR1XS
KINGS-1	NWDJN5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LIWGlEPTB;NT6wO\|c1PCEQvF2=	NFjTXIZUSU6JRWK=
HD-MY-Z	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrUNYhKSzVyPUWuNlM6PjlizszN	NFjQ[o1USU6JRWK=
ESS-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfnZ2RlUUN3ME21MlI2PTl5IN88US=>	NHvi[JFUSU6JRWK=
GI-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PPVWlEPTB;NT6yO\|kzPiEQvF2=	NXnrfGlzW0GQR1XS
RPMI-2650	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHCc5RKSzVyPUWuN\|YyPiEQvF2=	NUnOVoVxW0GQR1XS
IA-LM	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTJTWM2OD13LkO5PFcyKM7:TR?=	MkTZV2FPT0WU
KP-4	NHPDdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTVwNE[zN\|Qh\|ryP	NV7IXoxUW0GQR1XS
G-402	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXri[FBuUUN3ME21MlUyQDZ3IN88US=>	M{DvSHNCVkeHUh?=
OS-RC-2	NH30PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTVwNUK2NFQh\|ryP	M2jKVXNCVkeHUh?=
NCI-H1155	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3wVmF7UUN3ME21MlU1QTV3IN88US=>	NW\OW2ZMW0GQR1XS
OE19	M3PYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2noR2lEPTB;NT62PFYzPCEQvF2=	MYHTRW5ITVJ?
U-2-OS	NGraRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrvfIVKSzVyPUWuPFkxOTNizszN	M1TOWHNCVkeHUh?=
SCC-15	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTzW4hIUUN3ME21Mlk{PjZ{IN88US=>	MXLTRW5ITVJ?
NCI-H630	NU\uPGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[yTWM2OD13Lkm5OFA1KM7:TR?=	MX3TRW5ITVJ?
PFSK-1	M{C4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTZwMEWyOVkh\|ryP	M{m1WnNCVkeHUh?=
NCI-H1770	NGjRdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\HU3dKSzVyPU[uNlA5PzRizszN	Ml65V2FPT0WU
SK-MEL-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTZwNEK5NVUh\|ryP	MXvTRW5ITVJ?
LB1047-RCC	NUjPfGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjCZ\|dKSzVyPU[uOFc3OjVizszN	M1fMZXNCVkeHUh?=
NCI-H446	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HZdmlEPTB;Nj62NlkzPSEQvF2=	NVKxNpc1W0GQR1XS
SW780	M2TOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTZwN{CxPFUh\|ryP	NF\6SIhUSU6JRWK=
NEC8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHBTWM2OD14Lke2OlMh\|ryP	NYXjUZAzW0GQR1XS
NOMO-1	M{OxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfGT2FKSzVyPU[uO\|gyOTFizszN	MVPTRW5ITVJ?
COLO-668	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\a[ppKSzVyPU[uPFQ{QDdizszN	MlXHV2FPT0WU
MC116	NGS3NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13uNGlEPTB;Nj65N\|g6PyEQvF2=	NWfZZ5Q6W0GQR1XS
HCC1937	NWjiXmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHlTWM2OD14Lkm5NlUyKM7:TR?=	Mn:wV2FPT0WU
NCI-N87	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3uxN2lEPTB;Nz6xPVI6OyEQvF2=	NEn3cZBUSU6JRWK=
COLO-320-HSR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITI[2VKSzVyPUeuNlI4OzhizszN	MnPBV2FPT0WU
HCC1806	M1KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37w[2lEPTB;Nz6yOlA1PCEQvF2=	MlzBV2FPT0WU
OVCAR-3	M1jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTdwM{OwN\|gh\|ryP	NES2N5NUSU6JRWK=
NUGC-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XiWWlEPTB;Nz6zPVY6PCEQvF2=	MU\TRW5ITVJ?
SW1783	NYPsVYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37EdGlEPTB;Nz60N\|E4PSEQvF2=	NV[2dGVGW0GQR1XS
GCT	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTdwNU[5NFYh\|ryP	NY[5eFdDW0GQR1XS
NCI-H2126	M3jiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTdwN{O2NlUh\|ryP	MYPTRW5ITVJ?
MEL-HO	NYHsbnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXTTWM2OD15Lke3NFU1KM7:TR?=	MnPYV2FPT0WU
CAPAN-1	M4TNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPBVZRLUUN3ME23Mlc4OzV5IN88US=>	NYL2dWFWW0GQR1XS
SW756	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTdwN{izN\|Mh\|ryP	M4\FR3NCVkeHUh?=
SKG-IIIa	NV7q[\|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPkTWM2OD15LkixPFkzKM7:TR?=	M1HYNnNCVkeHUh?=
HCE-T	NIO3VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PT[mlEPTB;Nz64O\|c5OyEQvF2=	NYq3UHl6W0GQR1XS
Ca-Ski	NVrsWGlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULXWYlzUUN3ME23Mlk6Ozh\|IN88US=>	MmfRV2FPT0WU
COLO-684	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLHR4pKSzVyPUiuNFE5OThizszN	NFnkbZpUSU6JRWK=
KYSE-70	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS3TWM2OD16LkC3O\|I6KM7:TR?=	NVrid4V7W0GQR1XS
TI-73	M3WxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:5TWM2OD16LkK1PFUyKM7:TR?=	MnjqV2FPT0WU
BT-20	NEn0T49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRThwMk[wOVIh\|ryP	M3myU3NCVkeHUh?=
MHH-ES-1	NVvlNm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT5TWM2OD16LkWxPFM1KM7:TR?=	M2jidXNCVkeHUh?=
TE-12	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoiyTWM2OD16LkW5PVMyKM7:TR?=	NYLhc2lYW0GQR1XS
YH-13	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRThwNkGwNFgh\|ryP	M3XFb3NCVkeHUh?=
SF126	NXr2OnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X0[WlEPTB;OD64N\|g3PSEQvF2=	NYHmbllxW0GQR1XS
J82	NXvJVoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e5XWlEPTB;OD65NFA{QCEQvF2=	NIHpSVRUSU6JRWK=
RCC10RGB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;WZWlEPTB;OD65PVU3OSEQvF2=	NFjTcoNUSU6JRWK=
SK-UT-1	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTlwMES5OFUh\|ryP	M2ezZnNCVkeHUh?=
LB2241-RCC	M4TZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\vfGlEPTB;OT6xPVE{PyEQvF2=	NVf4TGE3W0GQR1XS
LB996-RCC	NUTxbmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTlwMUm4PUDPxE1?	NEPib4tUSU6JRWK=
EPLC-272H	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXv2[2hLUUN3ME25MlM4PjV5IN88US=>	NGL0VmZUSU6JRWK=
CTV-1	M{jiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDRd21KSzVyPUmuOVY2OzJizszN	NXrkNYh{W0GQR1XS
HSC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILjWGlKSzVyPUmuOVc2PSEQvF2=	MWDTRW5ITVJ?
SK-MEL-28	NVezRWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33rOWlEPTB;OT62NVg6OyEQvF2=	MkG3V2FPT0WU
MMAC-SF	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3LN2dEUUN3ME25MlY5PzVizszN	NGjnUXBUSU6JRWK=
CP50-MEL-B	NYjCc29MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTlwN{W3PFIh\|ryP	NVHVT3pzW0GQR1XS
HT-1080	NYmweJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7BbIYxUUN3ME25Mlc4PzN7IN88US=>	MY\TRW5ITVJ?
HEC-1	M{Cw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ixS2lEPTB;MUCuN\|M2OiEQvF2=	Mn;QV2FPT0WU
AGS	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTFyLkO3OEDPxE1?	MV7TRW5ITVJ?
GAMG	M1HEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFyLkWxOlIh\|ryP	NYfae5dnW0GQR1XS
SW48	NEm5[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLxeFBKSzVyPUGwMlUyQDlizszN	MXPTRW5ITVJ?
U031	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfIfpFKSzVyPUGwMlU6ODhizszN	NInET5lUSU6JRWK=
OVCAR-5	M1i2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvVTWM2OD1zMD62OFI6KM7:TR?=	NV;wUm1OW0GQR1XS
SF295	NFXxOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\OTWM2OD1zMD62O\|A1KM7:TR?=	MoPNV2FPT0WU
BHT-101	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLBTWM2OD1zMD63NVc4KM7:TR?=	M1zuNXNCVkeHUh?=
VMRC-RCZ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DTVGlEPTB;MUGuN\|IxOSEQvF2=	Mmn3V2FPT0WU
ACHN	M1nMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTFzLkSyNVEh\|ryP	MnrxV2FPT0WU
NCI-H526	NWjD[HRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnS[3FUUUN3ME2xNU42ODR\|IN88US=>	MYTTRW5ITVJ?
MN-60	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4L3RmlEPTB;MUGuOVM6KM7:TR?=	MnK0V2FPT0WU
NCI-H2291	NEPkclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\GOIpXUUN3ME2xNU42PDZ4IN88US=>	NEHZZYFUSU6JRWK=
SCC-25	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;5cYNKSzVyPUGxMlc2PTZizszN	MUPTRW5ITVJ?
SK-MEL-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEGxTFFKSzVyPUGxMlc3OzdizszN	M3[3S3NCVkeHUh?=
SN12C	NFLjOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPvTWM2OD1zMT65N\|U2KM7:TR?=	MonZV2FPT0WU
NCI-H69	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rrWmlEPTB;MUKuOFI{PCEQvF2=	NWfReGkyW0GQR1XS
ME-180	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX24OHg{UUN3ME2xNk44ODV2IN88US=>	MlHaV2FPT0WU
MC-IXC	NYXOc4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;wNFQ{UUN3ME2xNk44PTF6IN88US=>	NXrFSZFoW0GQR1XS
NCI-H2347	NXPuc412T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTJTWM2OD1zMj63OlE1KM7:TR?=	M1O4VXNCVkeHUh?=
M059J	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLSOW11UUN3ME2xNk44PzJ5IN88US=>	MVvTRW5ITVJ?
A2058	M{DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTF{Lki2PFEh\|ryP	NVjiWGdQW0GQR1XS
VA-ES-BJ	NXzkcJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHidIlKSzVyPUGyMlg4QDVizszN	MnzuV2FPT0WU
Ca9-22	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3hO2VKSzVyPUGyMlk1PTFizszN	M1PDR3NCVkeHUh?=
KNS-42	NFPOZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3hTWM2OD1zMj65PVg1KM7:TR?=	NFm4VphUSU6JRWK=
LoVo	M33nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTKTWM2OD1zMz6yN\|E{KM7:TR?=	NGCzb3lUSU6JRWK=
AM-38	M3jLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTF\|LkK1OlYh\|ryP	NHvJRWtUSU6JRWK=
NB5	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfwbpFnUUN3ME2xN{4{PzV{IN88US=>	NYnFRWwyW0GQR1XS
L-363	NVnlc2V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G3S2lEPTB;MUOuOFA{OyEQvF2=	M3HNd3NCVkeHUh?=
SK-MEL-30	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorsTWM2OD1zND6wOlQ2KM7:TR?=	M3y4SHNCVkeHUh?=
NCI-H1563	M{\lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkO5TWM2OD1zND62NFM6KM7:TR?=	MnW2V2FPT0WU
NCI-H2228	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTF2Lk[wO\|ch\|ryP	Mn3IV2FPT0WU
MFM-223	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHLTWM2OD1zNT6xPFE{KM7:TR?=	MWTTRW5ITVJ?
LB831-BLC	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTNR5JKSzVyPUG1MlI4PjdizszN	M1vMe3NCVkeHUh?=
SW872	NE\ZUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnBc\|hvUUN3ME2xOU4{ODh4IN88US=>	M{DjS3NCVkeHUh?=
NCI-H522	Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LDOWlEPTB;MUWuN\|MxPiEQvF2=	NYL6e21iW0GQR1XS
EW-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\FR2lEPTB;MUWuOVQ3OiEQvF2=	MmT2V2FPT0WU
HN	NY\aVVljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTwOnZKSzVyPUG1MlU6PDJizszN	MlL3V2FPT0WU
SW837	M4\qbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj4TWM2OD1zNT63PFQ4KM7:TR?=	NUfYdJJJW0GQR1XS
SCC-9	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVOz[4Q4UUN3ME2xOU45OTF2IN88US=>	NWL5RpBzW0GQR1XS
MKN7	NH7GcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXyTWM2OD1zNT65O\|MzKM7:TR?=	MVLTRW5ITVJ?
KYSE-410	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETOWIpKSzVyPUG2MlU6OSEQvF2=	NUHUeIJOW0GQR1XS
SK-N-DZ	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTJWnNKSzVyPUG2MlYyOTZizszN	MlXaV2FPT0WU
COR-L105	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTF4Lk[1Nlgh\|ryP	M2DYVXNCVkeHUh?=
LB2518-MEL	M1zLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjtT2lpUUN3ME2xOk45Ozh7IN88US=>	NE[yXXNUSU6JRWK=
OVCAR-4	NIq5XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf1ZpNKSzVyPUG2Mlg5PjJizszN	Ml3kV2FPT0WU
TK10	M4OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf5eGN6UUN3ME2xOk46PDd\|IN88US=>	Moj1V2FPT0WU
KNS-62	NGS0SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXiTWM2OD1zNj65O\|c4KM7:TR?=	NWi5dFJtW0GQR1XS
RPMI-8866	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LEZWlEPTB;MUeuNVc{OiEQvF2=	NEfuR4lUSU6JRWK=
HuP-T4	M1v4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rVVGlEPTB;MUeuNlQ6PSEQvF2=	NIDpRnNUSU6JRWK=
CGTH-W-1	NWfWd4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTF5LkWyNVkh\|ryP	NWrYTXVpW0GQR1XS
T-24	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET4co1KSzVyPUG3MlU{PDdizszN	MlTKV2FPT0WU
HT-3	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjQRnk1UUN3ME2xO{42QTF2IN88US=>	M3PCUnNCVkeHUh?=
KS-1	NXq2PYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LUVWlEPTB;MUeuOlc{KM7:TR?=	NG[weXNUSU6JRWK=
NCI-H1792	M3PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTF5Lke5PEDPxE1?	MoHPV2FPT0WU
ABC-1	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW[1OWN7UUN3ME2xO{45OTRzIN88US=>	MWDTRW5ITVJ?
BPH-1	NXH3TGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfFXHZKSzVyPUG4MlE3QDVizszN	MXrTRW5ITVJ?
A431	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF6LkSxNlch\|ryP	MmfNV2FPT0WU
T98G	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF6LkWxOVch\|ryP	MUHTRW5ITVJ?
BHY	NYPvVnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTF6Lki2PUDPxE1?	MVjTRW5ITVJ?
Capan-2	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP1UFdKSzVyPUG4MlkxPzhizszN	MmHKV2FPT0WU
MDA-MB-175-VII	M3\UUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W2[2lEPTB;MUiuPVIxQSEQvF2=	MXPTRW5ITVJ?
CAL-27	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVixcFViUUN3ME2xPU4xPDh5IN88US=>	NHLod4VUSU6JRWK=
AsPC-1	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fWS2lEPTB;MUmuPFY2PyEQvF2=	MkTVV2FPT0WU
KU812	M4D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfnNpdKSzVyPUG5Mlk2PzNizszN	NW\LWVJkW0GQR1XS
NCI-H441	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3IdIpKSzVyPUKwMlAxOSEQvF2=	NY\GflRuW0GQR1XS
Mewo	NYHtb2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTJyLkGyPFgh\|ryP	M2TBWnNCVkeHUh?=
SK-MEL-24	M{P3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PiTmlEPTB;MkCuNVQ4PyEQvF2=	MVnTRW5ITVJ?
NCI-H727	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTJyLkK3NFQh\|ryP	MWrTRW5ITVJ?
EKVX	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXsWHpYUUN3ME2yNE43ODZizszN	MXvTRW5ITVJ?
RT-112	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLndmdOUUN3ME2yNE43OTJ{IN88US=>	NEC1NHFUSU6JRWK=
CAMA-1	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;pdlNKSzVyPUKwMlk5ODNizszN	M3rpeHNCVkeHUh?=
SW900	M1S5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnj[3ZKSzVyPUKxMlAyPDlizszN	M3vhPHNCVkeHUh?=
NCI-H23	M{n2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;lcWlEPTB;MkGuNVI4PyEQvF2=	NUL2PXdDW0GQR1XS
SK-PN-DW	M16zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnSTWM2OD1{MT6xOlQ6KM7:TR?=	MlLxV2FPT0WU
BB30-HNC	NYfsWZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvIPYlGUUN3ME2yNU4zPzR3IN88US=>	NVvVW25KW0GQR1XS
VM-CUB-1	NYq5R25vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLxbWpKSzVyPUKxMlM2OzZizszN	NF:3TmNUSU6JRWK=
IST-MEL1	NVyzRlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TlcWlEPTB;MkGuN\|Y6OiEQvF2=	M2jz[nNCVkeHUh?=
CTB-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NImwNWNKSzVyPUKxMlQ4PTVizszN	M4HmbHNCVkeHUh?=
LCLC-103H	M4PuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJ{LkG1PFIh\|ryP	MmTLV2FPT0WU
PANC-03-27	NViydWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITpWmhKSzVyPUKyMlUyPjlizszN	NIfkcpVUSU6JRWK=
HTC-C3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\rfIRnUUN3ME2yNk42PTV3IN88US=>	NFr4cYRUSU6JRWK=
TE-8	NF6yO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH73WJBKSzVyPUKzMlI2PjVizszN	MYXTRW5ITVJ?
NCI-H292	NYLFdlNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLCZVg4UUN3ME2yOU4{PTN4IN88US=>	MnHWV2FPT0WU
COLO-680N	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHns[2FKSzVyPUK1MlY{OjlizszN	MlPHV2FPT0WU
KYSE-520	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvHTWM2OD1{NT62OFQh\|ryP	M{P2PHNCVkeHUh?=
NB10	NYnWcplbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH2TWM2OD1{Nj6zNVE4KM7:TR?=	MoP5V2FPT0WU
NCI-H661	NX:1Z3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrw[lJKSzVyPUK2MlQ4OTNizszN	M1KzRnNCVkeHUh?=
GMS-10	MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXTepNKUUN3ME2yOk45PjN6IN88US=>	M13neHNCVkeHUh?=
NCI-H2122	NYrx[WF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjv[25KSzVyPUK2Mlk6QThizszN	M17wR3NCVkeHUh?=
OVCAR-8	M2rDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJ5LkC2N\|gh\|ryP	NEjnUVNUSU6JRWK=
DJM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILIS45KSzVyPUK3MlE1PTRizszN	NVrI[IpVW0GQR1XS
UACC-893	NWi2dm14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnYT5RJUUN3ME2yO{46QDd6IN88US=>	NXTGbmFWW0GQR1XS
C8166	M3zUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO5ZXRSUUN3ME2yPE43QTN6IN88US=>	NF7nTldUSU6JRWK=
NCI-H1693	NULyWldkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTJ6Lk[5O\|Uh\|ryP	NXnhd4ZTW0GQR1XS
TYK-nu	M4\ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fJPGlEPTB;M{CuNFM1PSEQvF2=	M2GweHNCVkeHUh?=
SW1710	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;zd4RKSzVyPUOwMlEzPiEQvF2=	NGDqPZZUSU6JRWK=
A375	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXO[5hKSzVyPUOwMlMzPDNizszN	NWXGS\|V7W0GQR1XS
HMV-II	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjjTWM2OD1\|MT6zOVkzKM7:TR?=	M4D0[3NCVkeHUh?=
NCI-H2087	NXH3PVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fLfGlEPTB;M{GuOlM2OiEQvF2=	NGTHNJFUSU6JRWK=
CAL-54	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXqSYNKSzVyPUOxMlczPDFizszN	M3O5dHNCVkeHUh?=
HCC70	NFPW[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i3UmlEPTB;M{KuNVM5PyEQvF2=	NIrOeWJUSU6JRWK=
ES1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTN{LkOwOlIh\|ryP	NVPoNm9wW0GQR1XS
NCI-H1355	NWPzSpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLmSnFKSzVyPUOzMlIxPCEQvF2=	MV7TRW5ITVJ?
CFPAC-1	NEPRd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTN\|LkKzN\|Ih\|ryP	MX\TRW5ITVJ?
MKN28	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTN\|LkO4NFkh\|ryP	MkD1V2FPT0WU
HDLM-2	NEL3TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDlXWVKSzVyPUOzMlY6OzFizszN	NFnOWolUSU6JRWK=
PANC-10-05	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHm[pNKSzVyPUO0MlExOTRizszN	MkfzV2FPT0WU
SAS	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILaTXdKSzVyPUO0MlQ2PjVizszN	M1\ReHNCVkeHUh?=
HCC1395	NG\ye2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjHU5ZKSzVyPUO0MlcyQDZizszN	MmHUV2FPT0WU
8305C	M2LMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVS3NIZHUUN3ME2zOU45PDF3IN88US=>	M3SySXNCVkeHUh?=
KM12	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXETWM2OD1\|Nj63OVQ4KM7:TR?=	NITSU21USU6JRWK=
SW1116	M2\KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDBNVV4UUN3ME2zO{42QTl{IN88US=>	MXTTRW5ITVJ?
SK-MEL-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\qTWM2OD1\|OD6zN\|g6KM7:TR?=	NWLqRZZPW0GQR1XS
HCC2218	M2PMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[3eXNKSzVyPUO4MlY2OTlizszN	M4r3bXNCVkeHUh?=
T84	M4LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmiwTWM2OD1\|OD63OFA6KM7:TR?=	M1mzcnNCVkeHUh?=
ETK-1	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTN7LkCyNkDPxE1?	NYXHSmRSW0GQR1XS
COLO-800	NYLXUHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTN7LkO4Olgh\|ryP	MYHTRW5ITVJ?
CAL-12T	M1;qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XqfWlEPTB;M{muOVI5OSEQvF2=	NF2xN5JUSU6JRWK=
ACN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfyXVFoUUN3ME20NE41QTFzIN88US=>	MUjTRW5ITVJ?
SJSA-1	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7oTFFKSzVyPUSxMlE2QTZizszN	NVfYOow1W0GQR1XS
PSN1	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT2e2VKSzVyPUSxMlE4PDlizszN	NYS1ZVVuW0GQR1XS
D-566MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2e2eWlEPTB;NEGuNlA5PiEQvF2=	NWLEb\|NWW0GQR1XS
EGI-1	M3rP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTTTWM2OD12Mj60Nlgh\|ryP	MUnTRW5ITVJ?
A204	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPycIVKSzVyPUSyMlY{QDhizszN	NYLYZWo5W0GQR1XS
Saos-2	Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XaPGlEPTB;NEKuPFM3QSEQvF2=	NFT6UZNUSU6JRWK=
SNU-C2B	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEi2XIpKSzVyPUSzMlY5PzhizszN	M3L2VnNCVkeHUh?=
HLE	M1S4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjXTWM2OD12ND6wPFU3KM7:TR?=	MXHTRW5ITVJ?
SW1463	NF3tV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvIUopVUUN3ME20OE46QTdzIN88US=>	M4DicXNCVkeHUh?=
DSH1	NX71XXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jOZWlEPTB;NEWuNFA{OyEQvF2=	M3j3d3NCVkeHUh?=
MCF7	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7PTWM2OD12NT61NFUyKM7:TR?=	MYTTRW5ITVJ?
K5	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDWWXpKSzVyPUS1Mlk1ODVizszN	NF3GSXFUSU6JRWK=
NCI-H358	NHniSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETQUXFKSzVyPUS3MlIyPSEQvF2=	NYOwOZVnW0GQR1XS
NCI-H2030	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXTTWM2OD12Nz6yN\|c1KM7:TR?=	MnzMV2FPT0WU
SW948	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTR5LkS2OEDPxE1?	MVnTRW5ITVJ?
BALL-1	M2rQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jwSmlEPTB;NEeuOlE3QCEQvF2=	NV7RfG1VW0GQR1XS
TE-9	M2H1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTR5Lkm1PFEh\|ryP	MV3TRW5ITVJ?
SK-N-FI	NYfHXYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTqVnhnUUN3ME20PE4xOzV6IN88US=>	MX7TRW5ITVJ?
KALS-1	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTR6LkGyPFkh\|ryP	NIPtZ\|BUSU6JRWK=
HO-1-N-1	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;1[2JYUUN3ME20PE44PDR3IN88US=>	M{[3VnNCVkeHUh?=
NCI-H2452	NWHMT5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnJTWM2OD12OT6xNVUzKM7:TR?=	M1nwe3NCVkeHUh?=
OC-314	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\t[45KSzVyPUS5MlY5OzRizszN	NGn1fY5USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Small Cell Lung Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 28 2017	Phase 1
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2
NCT02520778	Recruiting	EGFR Activating Mutation\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.G719X\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.L861Q\|EGFR NP_005219.2:p.T790M\|Stage III Non-Small Cell Lung Cancer AJCC v7\|Stage IIIA Non-Small Cell Lung Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Non-Small Cell Lung Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Active not recruiting	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02143401	Recruiting	Cirrhosis\|Hepatitis B Infection\|Hepatitis C Infection\|Metastatic Malignant Solid Neoplasm\|Recurrent Hepatocellular Carcinoma\|Recurrent Malignant Solid Neoplasm\|Refractory Malignant Neoplasm\|Stage IV Hepatocellular Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 7 2014	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 43 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 43 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)